Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.
Milone G, Tripepi G, Martino M, Ancora F, Bartolozzi B, Spadaro A, Nozzoli C, La Fauci A, Amico I, Leotta S, Poidomani M, Irrera G, Iacopino P, Saccardi R, Guidi S, Bosi A. Milone G, et al. Among authors: spadaro a. Blood Transfus. 2013 Jan;11(1):94-101. doi: 10.2450/2012.0004-12. Epub 2012 Oct 10. Blood Transfus. 2013. PMID: 23114516 Free PMC article.
Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.
Milone G, Poidomani M, Leotta S, Avola G, Camuglia MG, Privitera A, Consoli C, Mercurio S, Romeo MA, Di Marco A, Di Mercurio S, Spadaro A, Palumbo GA, Tedeschi P. Milone G, et al. Among authors: spadaro a. Bone Marrow Transplant. 2012 Jan;47(1):24-32. doi: 10.1038/bmt.2011.33. Epub 2011 Mar 14. Bone Marrow Transplant. 2012. PMID: 21399670
Chemosensitivity of nonleukemic clonogenic precursors in AML patients in complete remission: association with CD34(+) mobilization and with disease-free survival.
Milone G, Avola G, Leotta S, Strano A, Camuglia MG, Pinto V, Mercurio S, Poidomani M, Coppoletta S, Di Marco AL, Consoli C, Triolo A, Spadaro A, Privitera A, Ragusa A, Tibullo D, Di Mercurio S. Milone G, et al. Among authors: spadaro a. Exp Hematol. 2012 Jan;40(1):35-47.e2. doi: 10.1016/j.exphem.2011.10.002. Epub 2011 Oct 20. Exp Hematol. 2012. PMID: 22019627 Free article.
Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, Cupri A, Di Martina V, Schinocca E, Spina E, Tripepi G. Milone G, et al. Among authors: spadaro a. Br J Haematol. 2014 Jan;164(1):113-23. doi: 10.1111/bjh.12606. Epub 2013 Oct 21. Br J Haematol. 2014. PMID: 24138497 Free article.
Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.
Milone G, Martino M, Leotta S, Spadaro A, Zammit V, Cupri A, Avola G, Camuglia MG, Di Marco A, Scalzulli P, Morelli M, Olivieri A, Tripepi G. Milone G, et al. Among authors: spadaro a. Leuk Lymphoma. 2018 Jan;59(1):42-48. doi: 10.1080/10428194.2017.1324161. Epub 2017 Jun 2. Leuk Lymphoma. 2018. PMID: 28573902 Clinical Trial.
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, Di Raimondo F, Milone G. Pirosa MC, et al. Among authors: spadaro a. Chemotherapy. 2018;63(4):220-224. doi: 10.1159/000492941. Epub 2018 Oct 29. Chemotherapy. 2018. PMID: 30372691
Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost.
Milone G, Conticello C, Leotta S, Michieli MG, Martino M, Marco ALD, Spadaro A, Cupri A, Condorelli A, Milone GA, Markovic U, Sciortino R, Schininà G, Moschetti G, Villari L, Saccardi R; for GITMO. Milone G, et al. Among authors: spadaro a. Leuk Res Rep. 2020 Oct 30;14:100227. doi: 10.1016/j.lrr.2020.100227. eCollection 2020. Leuk Res Rep. 2020. PMID: 33204611 Free PMC article.
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Mina R, Petrucci MT, Bonello F, Bongarzoni V, Saccardi R, Bertuglia G, Mengarelli A, Spadaro A, Lisi C, Curci P, Lemoli RM, Ballanti S, Floris R, Cupelli L, Tosi P, Olivieri A, Rota-Scalabrini D, Cangialosi C, Nozzoli C, Anaclerico B, Fazio F, Bruno B, Mancuso K, Corradini P, Milone G, Boccadoro M. Mina R, et al. Among authors: spadaro a. Haematologica. 2024 May 1;109(5):1525-1534. doi: 10.3324/haematol.2023.284023. Haematologica. 2024. PMID: 37981892 Free PMC article.
311 results